The overall goal of AVITHRAPID is to establish a community of practice comprising the infrastructure, expertise and complete range of stakeholders relevant to discover, develop and manufacture antiviral compounds. It is the ambition of AVITHRAPID to assemble and operate a complete, harmonized and accessible value chain integrating the scientific, methodological, financial, regulatory, intellectual property, production and logistics aspects as key tool for pandemic preparedness and response approach.

This includes:

• Regulatory Framework: Addressing existing barriers across the EU, with special focus on pharmaceutical incentives and legislation, marketing authorisation, HTA as well as pricing and reimbursement processes.
• Research and innovation policy: Identify major antiviral therapeutics development needs in relation to funding, including potential gaps and opportunities for joint calls. Develop innovative co-funding models, new funding streams, and/or social impact financial tools to prepare for the implementation of a (pilot) international funding call.
• Funders network: Bringing together public funders, disease-focused charities, generalist philanthropies and industry partners to share best practices, co-ordinate funding streams and promote joint calls
• Equitable access: Supporting science and policy leadership to strengthen existing and emerging innovation ecosystems that prioritize the needs of neglected populations and ensure innovations originating in low or middle income countries are integrated into international responses.
• Design of a legal entity: The foundation of a non-for-profit organization by the end will allow for further exploitation, collecting all the values created in AVITHRAPID becoming a competence centre and small and medium-sized enterprises (SME) accelerator. This will involve establishing intellectual property, licensing and collaboration agreements, funding and operational plans and implementing a governance structure that induces transparency and trust.
• Open Science: Promoting the broadest possible sharing of research knowledge and data across the innovation lifecycle to ensure value for public investments, accelerate science, and bring solutions for patients as well as accelerate and reduce the cost of research and development
• Collaboration: Ensuring a wide external participation by organising a broad range of networking activities including all stakeholders and civil society, requiring that any publication deriving from AVITHRAPID will be open access.